The health ministry of Israel has identified less than 10 cases of heart inflammation following a third dose of the Pfizer (NYSE:PFE)/BioNtech (Nasdaq:BNTX) COVID-19 vaccine, Reuters news agency reported on Friday.
In data published late on Thursday, the health ministry reported nine cases of myocarditis within four age groups that comprised more than 1.5 million people who had received a booster shot.
All were male, three were between the ages of 16 and 29 and six were in the 30-59 group. Eight more possible cases were still being reviewed. Most myocarditis cases are generally mild, the health ministry said.
In total, out of all 3.2 million Israelis who have received a third jab, 25 reported serious adverse events that appeared within 30 days of the shot, including myocarditis, though a causal link had yet to be established among many of them.
Israel began administering boosters to risk groups in July and later expanded its campaign to include anyone over the age of 12, five months or more after a second dose.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP